Thompson Siegel & Walmsley LLC Xeris Biopharma Holdings, Inc. Transaction History
Thompson Siegel & Walmsley LLC
- $6.01 Billion
- Q2 2025
A detailed history of Thompson Siegel & Walmsley LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Thompson Siegel & Walmsley LLC holds 266,387 shares of XERS stock, worth $2.14 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
266,387
Previous 172,784
54.17%
Holding current value
$2.14 Million
Previous $949,000
31.09%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding XERS
# of Institutions
207Shares Held
89.4MCall Options Held
81.6KPut Options Held
57.6K-
Black Rock Inc. New York, NY10.3MShares$83 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$78.8 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.84MShares$30.8 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$30.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.65MShares$29.3 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $1.09B
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...